Alanno plant flags

Home News & Media

News & Media

Filter by

Sort:

people looking at some R&D tools

Linerixibat recommended for EU approval by the CHMP for the treatment of cholestatic pruritus in adult patients with primary biliary cholangitis (PBC).

Alfasigma building

Alfasigma Completes Agreement with GSK for linerixibat

Alfasigma Streamlines Manufacturing Footprint to Sharpen Strategic Focus and Accelerate Innovation and Growth

Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%)[1], Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets.

Alfasigma building

Linerixibat approved for use in the U.S. for the treatment of cholestatic pruritus in primary biliary cholangitis (PBC)

Alfasigma building

GSK and Alfasigma announce agreement on worldwide rights for linerixibat

Alfasigma building

Alfasigma Secures Exclusive Rights from Innovative Molecules to Parenteral Adibelivir for Treatment of HSV Encephalitis, an Ultra-Rare Disease

Open Access for Alfasigma’s scientific publications

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

Media support

Need support from the press office?

Contact the team

Media centre